To this aim, experimental studies using in vivo models resembling human pancreatic cancer are required to proof a causal connection between expression and activity of transporters such as MRP5 and tumor resistance to 5-FU and gemcitabine. This evidence concerns the gene ABCC5 and familial pancreatic carcinoma.